Advice
in the absence of a submission from the company
oestrogens, conjugated, bazedoxifene acetate (Duavive®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.
The company has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice58KB (PDF)
Medicine details
- Medicine name:
- oestrogens, conjugated, bazedoxifene acetate (Duavive)
- SMC ID:
- 1220/17
- Indication:
- Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.
- Pharmaceutical company
- MSD Limited / Pfizer Limited
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 16 January 2017